Tnx-102 Sl
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Tonix Pharmaceuticals, Inc.Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Immulina Tm University of Mississippi Medical Center | Phase 3 | BB |
MELATONIN Duke University | Phase 2 | B |
Rapamycin Icahn School of Medicine at Mount Sinai | Phase 3 | B |
Paxlovid Kanecia Obie Zimmerman | Phase 2 | B |
RITONAVIR Kanecia Obie Zimmerman | Phase 2 | B |
View all 31 →
Same molecule, other indications
Tnx-102 Sl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →